Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
about
Acute lymphoblastic leukaemiaA health-care system perspective on implementing genomic medicine: pediatric acute lymphoblastic leukemia as a paradigmIKZF1 deletions predict relapse in uniformly treated pediatric precursor B-ALL.Childhood Acute Lymphoblastic Leukemia: Progress Through CollaborationSurvival improvement by decade of patients aged 0-14 years with acute lymphoblastic leukemia: a SEER analysis.Incidence and survival rates of hematological malignancies in Japanese children and adolescents (2006-2010): based on registry data from the Japanese Society of Pediatric Hematology.Immature MEF2C-dysregulated T-cell leukemia patients have an early T-cell precursor acute lymphoblastic leukemia gene signature and typically have non-rearranged T-cell receptors.Evaluation of Endocrine Late Complications in Childhood Acute Lymphoblastic Leukemia Survivors: A Report of a Single-Center Experience and Review of the LiteratureManagement of adult and paediatric acute lymphoblastic leukaemia in Asia: resource-stratified guidelines from the Asian Oncology Summit 2013.Prognostic factors and treatment of pediatric acute lymphoblastic leukemia.Pharmacogenetic risk factors for altered bone mineral density and body composition in pediatric acute lymphoblastic leukemia.Methotrexate-induced side effects are not due to differences in pharmacokinetics in children with Down syndrome and acute lymphoblastic leukemia.Cranial radiation for pediatric T-lineage acute lymphoblastic leukemia: a systematic review and meta-analysis.Expression of CD25 is a specific and relatively sensitive marker for the Philadelphia chromosome (BCR-ABL1) translocation in pediatric B acute lymphoblastic leukemia.Prevention of bone growth defects, increased bone resorption and marrow adiposity with folinic acid in rats receiving long-term methotrexate.Improved prognosis for older adolescents with acute lymphoblastic leukemia.Biology, risk stratification, and therapy of pediatric acute leukemias: an update.The negative impact of being underweight and weight loss on survival of children with acute lymphoblastic leukemia.Health status utilities in pediatrics: a systematic review of acute lymphoblastic leukemia.Impaired sleep affects quality of life in children during maintenance treatment for acute lymphoblastic leukemia: an exploratory studyChallenging issues in pediatric oncologyMethotrexate resistance in relation to treatment outcome in childhood acute lymphoblastic leukemia.Transplantation Outcomes for Children with Hypodiploid Acute Lymphoblastic Leukemia.Dexamethasone exposure and asparaginase antibodies affect relapse risk in acute lymphoblastic leukemia.Glucocorticoid use in acute lymphoblastic leukaemiaImproved survival for children and adolescents with acute lymphoblastic leukemia between 1990 and 2005: a report from the children's oncology group.Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone.Pediatric acute lymphoblastic leukemia: where are we going and how do we get there?The significance of PTEN and AKT aberrations in pediatric T-cell acute lymphoblastic leukemia.Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia.Aggravated bone density decline following symptomatic osteonecrosis in children with acute lymphoblastic leukemiaAdvances in paediatric cancer treatmentIncidence and risk factors for central nervous system relapse in children and adolescents with acute lymphoblastic leukemia.Health-related quality of life and utility scores in short-term survivors of pediatric acute lymphoblastic leukemiaMinimal Residual Disease Evaluation in Childhood Acute Lymphoblastic Leukemia: An Economic Analysis.Influence of Cranial Radiotherapy on Outcome in Children With Acute Lymphoblastic Leukemia Treated With Contemporary TherapyThe low incidence of secondary acute myelogenous leukaemia in children and adolescents treated with dexrazoxane for acute lymphoblastic leukaemia: a report from the Dana-Farber Cancer Institute ALL Consortium.A 50-year journey to cure childhood acute lymphoblastic leukemiaNeurocognitive outcomes decades after treatment for childhood acute lymphoblastic leukemia: a report from the St Jude lifetime cohort study.Controversies in the management of central nervous system leukemia.
P2860
Q24602387-166EEF56-765E-41D7-9C19-32DA43C1752CQ26866379-3B86AA7D-BDC9-4E68-95F9-C07AF656866AQ27851563-433FAC9B-4B31-4D07-8490-7E0C9E3C8FA9Q28087637-B1F9F158-FD70-427C-A9FE-DB5E5E131D7FQ30572783-5F94A497-15C5-4762-B084-E995316D3C45Q30631947-9F17A328-ED41-4B30-8D6D-49AF84CAF819Q33558120-F4060217-1AFB-48ED-A95B-567E0F120E0CQ33747806-FF9A1820-ECD1-46BD-8ACB-ACCB05A1F474Q33762835-9D45AF9B-8560-44D9-AC6F-52F6FCBA5FE4Q33770150-D3A329BA-2D94-4934-8685-09E9C21E4C7EQ33829083-57969D7C-A8BB-431C-B88B-5C20BA2157C0Q33952766-495C4DB2-A694-4011-AE3F-83731F8C4C83Q34203403-0D5C8FC8-EAB4-4476-91BA-A806FD8A586DQ34371730-9A99B41A-30FA-4BBA-A690-778C8409C91FQ34447588-F2F3B1E7-B9E8-4467-B521-8923438AB070Q34679298-F380C1D6-3A45-4229-96C6-5767C5F4D878Q34764504-28D5EFFC-6742-4A86-9923-0F4E40D05E12Q34798033-A2BF79D3-3424-410D-BE2D-C65150EAD479Q34866042-CB388AE4-910E-43CD-AD95-701D20572CD6Q34985645-9B963224-10C8-438C-A879-BBE11EC611D3Q35602419-3E4D6F78-78D4-4C5E-A43A-71165C37CF1CQ35684384-CD5F8EB1-8681-45DA-885A-A1AF4037AB80Q35738417-ABF5E487-7520-4FD3-A148-C38B718198F6Q35776973-1F9B4184-1E17-43B3-B36E-B830C8BD96B6Q35844745-9A982393-E472-48B4-809B-1D2A8F610DE7Q36058255-AE30C35F-12A1-4C6B-99CC-77B6F72F534FQ36064796-8B5E62C3-F0B4-4D8C-9A7E-CD35E384F704Q36163029-EAFB9951-5447-4CBE-9AE6-8D783FF6ECF7Q36216246-EFCBE712-D47D-4D3E-9D4E-FEF26F0B4672Q36287682-0F4F713E-2059-47EC-95A8-2FE3E8CE109DQ36337592-9AB14B1A-2D9B-4089-BC0E-4B48AD79C8C1Q36508630-80B3C877-9C92-4CAF-AC5F-A17ABF1FBC2CQ36534036-2061D413-76CF-4415-B5F1-BE1AFC612B86Q36714994-D5E66D0E-DC28-4B3C-A536-34CB9FA9CAA7Q36731638-5C1D0E8F-5D5A-4C80-87D3-6F7E5AEB74E6Q36914357-D5843FE4-E65B-41DD-BF93-3A6F63AB1552Q37078647-FE8624C2-A474-4C39-9626-92209E455672Q37166753-21D44922-86D4-4548-A450-C93B7338BAAEQ37348625-26139BBF-82E9-43F4-844E-0E3F17FA4F4FQ37752342-82082278-A0B2-4A79-BCF2-6214F0348439
P2860
Dexamethasone-based therapy for childhood acute lymphoblastic leukaemia: results of the prospective Dutch Childhood Oncology Group (DCOG) protocol ALL-9 (1997-2004).
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Dexamethasone-based therapy fo ...... G) protocol ALL-9 (1997-2004).
@en
Dexamethasone-based therapy fo ...... Dutch Childhood Oncology Group
@nl
type
label
Dexamethasone-based therapy fo ...... G) protocol ALL-9 (1997-2004).
@en
Dexamethasone-based therapy fo ...... Dutch Childhood Oncology Group
@nl
prefLabel
Dexamethasone-based therapy fo ...... G) protocol ALL-9 (1997-2004).
@en
Dexamethasone-based therapy fo ...... Dutch Childhood Oncology Group
@nl
P2093
P1433
P1476
Dexamethasone-based therapy fo ...... G) protocol ALL-9 (1997-2004).
@en
P2093
Anjo J Veerman
Anna van der Does-van den Berg
Carin M Korbijn
Dutch Childhood Oncology Group
Elisabeth R van Wering
Elisabeth T Korthof
Eva van den Berg
Henk van den Berg
J Fransje van Weerden
Jos P M Bökkerink
P304
P356
10.1016/S1470-2045(09)70228-1
P577
2009-09-09T00:00:00Z